PT  - JOURNAL ARTICLE
AU  - Alizon, Samuel
AU  - Selinger, Christian
AU  - Sofonea, Mircea T.
AU  - Haim-Boukobza, Stéphanie
AU  - Giannoli, Jean-Marc
AU  - Ninove, Laetitia
AU  - Pillet, Sylvie
AU  - Vincent, Thibault
AU  - de Rougemont, Alexis
AU  - Tumiotto, Camille
AU  - Solis, Morgane
AU  - Stephan, Robin
AU  - Bressollette-Bodin, Céline
AU  - Salmona, Maud
AU  - L’Honneur, Anne-Sophie
AU  - Behillil, Sylvie
AU  - Lefeuvre, Caroline
AU  - Dina, Julia
AU  - Hantz, Sébastien
AU  - Hartard, Cédric
AU  - Veyer, David
AU  - Delagrèverie, Héloïse M
AU  - Fourati, Slim
AU  - Visseaux, Benoît
AU  - Henquell, Cécile
AU  - Lina, Bruno
AU  - Foulongne, Vincent
AU  - Burrel, Sonia
AU  - ,
TI  - Epidemiological and clinical insights from SARS-CoV-2 RT-PCR cycle amplification values
AID  - 10.1101/2021.03.15.21253653
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.03.15.21253653
4099  - http://medrxiv.org/content/early/2021/03/17/2021.03.15.21253653.short
4100  - http://medrxiv.org/content/early/2021/03/17/2021.03.15.21253653.full
AB  - The SARS-CoV-2 pandemic has led to an unprecedented daily use of molecular RT-PCR tests. These tests are interpreted qualitatively for diagnosis, and the relevance of the test result intensity, i.e. the number of amplification cycles (Ct), is debated because of strong potential biases. We analyze a national database of tests performed on more than 2 million individuals between January and November 2020. Although we find Ct values to vary depending on the testing laboratory or the assay used, we detect strong significant trends with patient age, number of days after symptoms onset, or the state of the epidemic (the temporal reproduction number) at the time of the test. These results suggest that Ct values can be used to improve short-term predictions for epidemic surveillance.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT04738331Funding StatementThis study did not receive any specific funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study has been approved by the Internal Review Board of the University Hospital of Montpellier (France).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData will be made available upon publication of the manuscript.